Science Corp., Another Braintech Startup Founded By Neuralink Alums, Raises $230M Series C

2026-03-05 · Source: Artificial intelligence - Crunchbase News · Field: Technology & Digital — Artificial Intelligence & Machine Learning, Emerging Technologies & Innovation, Brain-Computer Interfaces · Depth: Fundamental Awareness, quick

Summary

Science Corp., a biotech startup specializing in brain-computer interface (BCI) technologies, has secured $230 million in a Series C funding round, bringing its total capital raised since 2021 to $489 million. The round included investors such as Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital. The company, reportedly valued at $1.5 billion, is developing both brain and retina implants, with its PRIMA BCI retinal implant clinical trial program expanding to include Stargardt disease and retinitis pigmentosa. Science Corp. also acquired microelectromechanical systems (MEMS) manufacturing assets in North Carolina, enabling in-house production of chips for neural interface devices, a strategy aimed at accelerating iteration and reducing costs compared to outsourcing.

Key takeaway

For investors evaluating biotech startups in the neural interface space, Science Corp.'s $230 million Series C and reported $1.5 billion valuation highlight strong market confidence. You should prioritize companies demonstrating vertical integration, like Science Corp.'s in-house MEMS manufacturing, as this strategy can accelerate product development and reduce operational risks, potentially leading to faster commercialization and higher returns.

Key insights

In-house manufacturing of neural interface components can accelerate development and reduce costs for BCI startups.

Principles

• Vertical integration can mitigate supply chain risks.
• Early clinical trial expansion broadens market reach.

Method

Science Corp. acquired MEMS facility assets to enable in-house manufacturing of chips for neural interface devices, aiming to accelerate iteration and reduce cost/risk compared to outsourcing.

In practice

• Consider in-house manufacturing for critical components.
• Expand clinical trials to cover related conditions.

Topics

• Brain-Computer Interface
• Retinal Implants
• Biotech Funding
• Neural Interface Devices
• MEMS Manufacturing

Best for: Investor, Entrepreneur, Business Analyst

Related on AIssential

• Neurosoft Bioelectronics raises $7.5M for scalable brain-computer interfaces — Neurosoft's soft, minimally invasive brain interfaces collect scalable, high-quality neural data to build cortical foundation models and improve clinical outcomes.
• $1B Funding for Spatial Intelligence Startup — Spatial intelligence, generating 3D virtual worlds from prompts, is advancing with significant investment and product launches.
• Tissium raises €30M in equity funding, €30M in debt — Tissium's biomorphic programmable polymers offer a non-invasive tissue repair solution, securing significant funding for US expansion.
• Exclusive: Fathom raises $47M, blending AI and physics in drug discovery - Endpoints News — Fathom Therapeutics combines AI and physics-based simulations to accelerate drug discovery.
• ‘The next big thing’: Newfund raises €60m to back brain technologies — Brain technologies represent a significant growth opportunity, driven by scientific maturity and advanced tools like AI.
• DeepMind spinout Isomorphic Labs raises $2.1bn — AI-driven drug discovery benefits from specialized teams and distinct corporate structures.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by Artificial intelligence - Crunchbase News.